




The Relationship of Chlamydia antigen, AD-like pathology, and Inflammation in the brains of intranasally infected BALB/c mice: a comparative study



Lindsey V. Weidmann¹, Brittany L. Kane¹, Brian J. Balin¹, Denah M. Appelt¹, Justin H. Schripsema², Christopher L. Smith², Kyle Ramsey² and C. Scott Little¹

¹Philadelphia College of Osteopathic Medicine and ²Microbiology Department, Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, Illinois 60515

Abstract

Alzheimer's Disease (AD) is characterized by amyloid deposition and inflammation. Chlamydia pneumoniae (Cpn) intranasal infection of BALB/c mice has been shown to induce AD-like pathology in brain tissue. Preliminary data suggests that other species of Chlamydia induce similar pathology in mice. Our objectives are to (1) identify and localize Chlamydia antigen and amyloid pathology in specific AD related brain regions of intranasally inoculated BALB/c mice infected with Cpn or Chlamydia muridarum (Cmu) and (2) evaluate the degree of glial cell activation in these regions. Non-transgenic BALB/c mice were intranasally inoculated with Cpn AR-39 (n=3) or Cmu (in vivo passaged Cmu (n=6) or stock Cmu (n=8)). Brain tissues were examined at day 60 for chlamydia specific labeling, amyloid pathology and glial cell activation using immunohistochemistry. At day 60, varying degrees of chlamydia and AD-like pathology were observed for both passaged Cmu and stock Cmu groups. Both groups had much higher antigen burden amyloid burden relative to titer negative mice. Glial cell activation was readily apparent in the brain where chlamydia and amyloid pathology had previously been localized. Cpn infected mice also displayed greater antigen burden and amyloid burden relative to titer negative mice which was consistent with Cmu findings. This suggests that mice with established Cmu infection were at greater risk for developing AD-like pathology. Activated glial cells in the Cmu infected brain tissues of both groups may be responsible for induction of AD-like pathology. These data possible demonstrate that intranasal infection with Chlamydia species induces inflammation and AD-like brain pathology.

Introduction

Alzheimer's disease (AD) is progressive neurodegenerative disease that affects one in eight older Americans. It is the most common form of dementia accounting for sixty to eighty percent of all cases and is the fifth leading cause of death for individuals age 65 and older. [1]. Due to its high prevalence, continued research on AD will be important in not only determining causes and risk factors but also developing treatment and improving patient's quality of life.

Alzheimer's disease is characterized by a progressive loss in cognitive function with the accumulation of the defining neuropathology amyloid (senile) plaques and neurofibrillary tangles in brain tissue. Decline in cognitive function is caused by neuronal cell death in areas of the brain associated with memory such as the medial temporal lobe and cortical structures. Neuronal cell death is induced by extracellular amyloid accumulation which disrupts normal synaptic communication within the brain. The formation of tangles within the neuron induces apoptosis by interfering with normal cellular function and transport of nutrients. Early AD pathology involves the medial temporal lobe which includes the hippocampus and the entorhinal cortex. [1,2]. Both of these regions are important for memory [3]. As the disease progresses, motor and sensory function become compromised and the disease is ultimately fatal [1].

There are two different forms of AD, sporadic and familial. Familial AD (FAD) accounts for less than 5% of AD cases and is caused by genetic mutations. Patients with FAD develop AD pathology before the age of 65. Genetic mutations associated with FAD involve mutations of the amyloid precursor protein and presenilin 1 and 2 [4]. A mutation in any of these proteins will lead to an early accumulation of amyloid plaques within brain tissue. [2,5]. While there is a known cause for FAD, the cause of sporadic AD which accounts for more than 95% of AD cases has not been identified. Several risk factors have been recognized including mild cognitive impairment, cardiovascular disease, head trauma, and inflammation. [2,6]. In 1998 Balin, Appelt and coworkers identified and infectious agent, *Chlamydia pneumoniae* (Cpn) in 17 of 19 AD brains, suggesting the potential role of infection in the induction or progression of AD [7].

Two members of the genus *Chlamydiae*, *C. trachomatis* and *C. pneumoniae*, play a role in acute and chronic human illness [8] and have been shown to induce a chronic inflammatory response. Following the establishment of a urogenital infection by *Chlamydia trachomatis*, this organism has also been implicated in reactive arthritis, a chronic inflammatory joint condition [9, 10]. *C. trachomatis* can also ascend from its primary site of infection in the lower genital tract to the fallopian tubes and cause complications such as pelvic inflammatory disease which may result in infertility [11,12]. *Chlamydia pneumoniae*, a respiratory pathogen, has been shown to establish chronic infection and has been implicated in coronary artery disease [13], multiple sclerosis [14], and AD [7]. Mouse models have shown that this strain of chlamydia can disseminate after intranasal inoculation. The bacterium travels via peripheral blood monocytes and macrophages and has been found in areas not typically associated with *C. pneumoniae*-respiratory infection such as the spleen, aorta, and abdominal lymph nodes [7,15]. Thus, the ability of *C. pneumoniae* to disseminate and establish chronic infection may promote pathology in tissues other than respiratory epithelium.

The presence of inflammation at sites of NSF deposition and NFT formation is a verified component of AD. There are two types of glial cells in the CNS that respond to increased Beta-Amyloid deposition that is seen in AD. Microglia act as the resident macrophages of the CNS and produce nitric oxide, reactive oxygen species (ROS), proinflammatory cytokines, and prostaglandins in the presence of Beta-Amyloid [16]. Astrocytes are the most abundant glial cells in the human brain and have more specialized functions than microglia; acting as supporting cells to the endothelial cells of the blood brain barrier, supply nutrients to nervous tissue, maintain extracellular ion balance, and are critical in the healing the CNS following traumatic injury [17]. Similar to microglia, astrocytes secrete various pro-inflammatory molecules including interleukins, prostaglandins and complement factors [17]. It has been hypothesized that astrocytes may sequester beta amyloid plaques serving as a protective barrier as well as contributing to microglial clearance of beta-amyloid deposits.

To address the potential role of Chlamydia in the induction of sporadic AD, this laboratory has developed a mouse model in which AD-like pathology is induced following the introduction of *C. pneumoniae*. This model involves intranasally infecting non-transgenic BALB/c mice with *C. pneumoniae* [18]. In contrast with transgenic mice, the use of BALB/c mice more accurately models the predominant form of AD (sporadic/late onset) because these mice do not harbor any (human) genes. Pathology is induced following infection with *C. pneumoniae* [18]. This bacterium is commonly associated with respiratory infections worldwide in humans and was first associated with AD following identification and isolation from post-mortem brain tissue of individuals with AD in 1998 [19]. This laboratory has shown that following intranasal infection of mice, this organism establishes a chronic infection in the olfactory bulbs and induces substantial pathological deposition of Aβ in the brain [18].

The work presented here continues previous studies involving the BALB/c mouse model of AD-like pathology following *C. pneumoniae* infection. The focus of this research is to investigate the presence of the respiratory adapted biovar of *C. muridarum*, in fixed and embedded mouse brain tissue previously infected with this organism. Analysis was conducted using immunohistochemistry to label *Chlamydia*-specific antigens, beta amyloid deposits, and glial cells followed by a semi-quantitative microscopic analysis of brain tissue. The goal of this work was to investigate the relationship between the relative amount and location of *Chlamydia* antigens and glial cells to that of AD-like pathology and to determine whether infection with *C. muridarum* induces AD-like pathology comparable to *C. pneumoniae*.

Methods

Chlamydia muridarum: Two different isolates of mouse adapted *Chlamydia trachomatis* Weiss strain were used to intranasally infect BALB/c mice at various concentrations. Group A mice were intranasally infected with 1 x 10⁹ or 1 x 10⁵ IFU of C Small Weiss (MoPn *in vivo* passage). Group B mice were intranasally infected with 1 x 10⁴ or 1 x 10⁵ IFU of mouse pneumonitis Weiss (MoPn stock strain).



Infection of Mice and Tissue Preparation: Mice were intranasally infected with either C Small Weiss or mouse pneumonitis. Mice were sacrificed 60 days p.i., brains were removed and immersion fixed in 4% paraformaldehyde, embedded in paraffin, and coronally sectioned at 7-10 micron thickness.

Mouse Brain Tissue: A total of 50 coronal brain sections were immunolabeled per mouse. Five sets of 10 sections: two sets were labeled with *C. trachomatis* specific antibody (10C-CR2104M1, 10C2104M3), two sets were labeled with beta-amyloid specific antibody (AB1-16 6E10, AB (H-43) SC9129) and one set did not receive primary antibody and was used as a negative control. In order provide representative samples from areas throughout the whole brain sections were selected every 70-100 microns from rostral (bregma + 2.22mm) to caudal (bregma -5.88mm) (Figure 1).

Antibodies: The primary antibodies specific for *C. trachomatis* used were: mouse monoclonal 10C-CR2104M1 at a working concentration of 2 micrograms/mL (Fitzgerald, Acton, MA), mouse monoclonal 10C-CR2104M3 at a working concentration of 2 micrograms/mL (Fitzgerald, Acton, MA). The primary antibodies that were used to detect B-Amyloid are: rabbit polyclonal sc-9129 at a working concentration of 4 micrograms/mL (Santa Cruz Biotechnology) and mouse monoclonal 6E10 at a working concentration of 2 micrograms/mL (Covance). The primary antibody used to label glial cells was: Rabbit anti-GFAP (novex, Life Technologies) at a working concentration of 2 micrograms/mL. To visualize the respected antigen alkaline phosphatase conjugated goat anti-mouse and anti-rabbit secondary antibodies were utilized (Life Technologies, Carlsbad, CA) at a dilution of 1:400 (1.25 micrograms/mL). Antibodies were diluted to working concentration using phosphate buffered saline+2% fetal bovine serum.

Immunohistochemistry: Mouse brain coronal sections were first rehydrated for 3 minutes in xylene 3x, followed by 100% ethanol x2, 90% ethanol x1, 70% ethanol x1 (Electron Microscopy Sciences, Fort Washington, PA). Next, slides were washed in DI H2O for 2 x 3 minutes, then placed in Citra antigen retrieval buffer (BioGenex, San Ramon, CA) and steamed at high pressure for 15 minutes at 120 degrees Celsius in a 2010 Retriever (Pick Cell Laboratories, Amsterdam, Netherlands). Slides remained in antigen retrieval buffer overnight at room temperature. Slides were washed with phosphate buffered saline pH 7.4 (PBS) 3 x 5 minutes. Next, Alkaline Phosphatase Horseradish Peroxidase was applied to the slides for 5 minutes to quench endogenous peroxidase activity, washed 3 x 5 minutes in PBS. Slides were incubated in mouse or mouse (MOM) blocking reagent (Vector Labs) was used 1 x 15 minutes. Following MOM, slides were blocked 1 x 15 minutes in PBS+2%FBS (Mediatech, Herndon, VA). Primary antibodies 10C-CR2104M1, 10C2104M3, Anti-C muridarum, AB1-16 6E10, AB (H-43) SC9129 were applied and slides placed in a humidified chamber at 37 degrees Celsius for 90 minutes. Next, slides were washed 3 x 5 minutes in PBS and blocked 2 x 15 minutes in 2% PBS+2%FBS. Secondary antibodies were applied to each slide and slides were incubated for 60 minutes in a humidified chamber at 37 degrees Celsius. Next, slides were washed 3 x 5 minutes in DI water (DI H2O). Slides were developed for 15 minutes using alkaline phosphatase new magenta (BioFX, Owings Mills, MD). Next, slides were washed in DI H2O 3 x 5 minutes and PBS 1 x 5 minutes. To stain the tissue Acidified Harris's Hematoxylin (Mercury free) was applied for 1 minute. The slides were rinsed briefly with DI H2O then washed with PBS for 5 minutes to produce a color change. Finally slides were washed 3 x 5 minutes w/ DI H2O then wiped down and air dried. Once dry slides were glycerol mounted and coverslipped.

Microscopic Analysis: Tissue was examined using 10x, 20x and 40x power objectives. Images were captured using NIS-Elements F 2.20 Imaging Systems software on a Nikon Eclipse 50i microscope using a Nikon Digital Sight DS-DM Camera.




Anatomic Location of Representative Coronal Sections
In panel A, red lines indicate the location of selected Coronal sections from the Mouse Brain Library, providing an analysis of the whole brain. Sections rostral (red circles) to bregma (yellow circle) and caudal to bregma (blue circles) are displayed. Particular regions of interest, related to Alzheimer's disease, are identified in panel B.

Results


| Section Location (mm) | Rostral | | | | | | | | | | Bregma | | | | | | | | | | Caudal | | | | | | | | | | |
|-----------------------|---------|------|------|-------|-------|-------|-------|-------|-------|-------|--------|------|------|-------|-------|-------|-------|-------|-------|-------|--------|------|------|-------|-------|-------|-------|-------|-------|-------|--|
| | 2.22 | 1.70 | 0.38 | -1.28 | -2.75 | -3.80 | -4.92 | -5.46 | -5.88 | Total | 2.22 | 1.70 | 0.38 | -1.28 | -2.75 | -3.80 | -4.92 | -5.46 | -5.88 | Total | 2.22 | 1.70 | 0.38 | -1.28 | -2.75 | -3.80 | -4.92 | -5.46 | -5.88 | Total | |
| 1 Mon Cpn | 22 | 10 | 22 | 18 | 23 | 42 | 9 | 6 | 2 | 154 | 18 | 15 | 19 | 5 | 26 | 21 | 20 | 10 | 0 | 134 | 11 | 11 | 13 | 22 | 5 | 9 | 9 | 4 | 7 | 91 | |
| Amyloid 2 Mon Cpn | 18 | 15 | 19 | 5 | 26 | 21 | 20 | 10 | 0 | 134 | 8 | 30 | 0 | 0 | 26 | 19 | 26 | 0 | 0 | 109 | 0 | 2 | 12 | 1 | 0 | 0 | 1 | 1 | 0 | 17 | |
| Amyloid 3 Mon Cpn | 11 | 11 | 13 | 22 | 5 | 9 | 9 | 4 | 7 | 91 | 0 | 11 | 13 | 15 | 13 | 10 | 10 | 1 | 3 | 76 | 0 | 0 | 0 | 1 | 3 | 0 | 5 | 0 | 0 | 9 | |
| Amyloid 4 Mon Cpn | 0 | 11 | 13 | 15 | 13 | 10 | 10 | 1 | 3 | 76 | 51 | 47 | 67 | 60 | 67 | 82 | 48 | 21 | 12 | 455 | 8 | 33 | 12 | 5 | 32 | 19 | 33 | 1 | 0 | 143 | |
| Amyloid Cpn Totals | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Chlamydia (Cpn) Antigen and Amyloid Deposition (Dep)
Location of *C. pneumoniae* immunoreactivity and amyloid deposits over 1, 2, 3, and 4 months post infection within brains of *C. pneumoniae*-infected mice. The location of immunoreactive label to amyloid deposits or *Chlamydia* antigen is designated in millimeters (Section location in mm) rostral or caudal to the mouse bregma. Gray, hatched, and aqua shaded areas highlight majority of *C. pneumoniae* antigen and the relationship to the majority of amyloid deposition 1 month later.

Results



Chlamydia muridarum Labeling
Chlamydia-specific labeling of CNS tissue of BALB/c mice inoculated i.n. with 100,000 of CSW (MoPn *in vivo* passaged) (A and C) or MoPn Weiss (MoPn stock strain) (B and D) immunolabeled with 10-CR2140M1. C. trachomatis specific antibody. E and F represent tier positive control tissue which were immunolabeled with 10-CR2140M1. Bar=50 microns.




Beta Amyloid Labeling
Chlamydia-specific labeling of CNS tissue of BALB/c mice inoculated i.n. with 100,000 of CSW (MoPn *in vivo* passaged) (A and C) or MoPn Weiss (MoPn stock strain) (B and D) immunolabeled with C. trachomatis specific antibody. E and F represent tier negative control tissue which were immunolabeled with 10-CR2140M1. Bar=50 microns.

| Section Location (mm) | Rostral | | | | | | | | | | Bregma | | | | | | | | | | Caudal | | | | | | | | | |
|--------------------------------------|---------|------|-------|-------|-------|-------|-------|-------------|------|---------|--------|-------|-------|-------|-------|-------------|-----|------|--|--|--------|--|--|--|--|--|--|--|--|--|
| | 1.32 | 0.00 | -1.28 | -2.75 | -3.80 | -4.92 | Total | Total/Mouse | 1.32 | 0.00 | -1.28 | -2.75 | -3.80 | -4.92 | Total | Total/Mouse | | | | | | | | | | | | | | |
| MoPn in vivo Day 60 p.i. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Titer Negative Infected mice (n=2) | Cmu Ag | - | 0 | 4 | 11 | 7 | - | 22 | 11 | Amyloid | - | 0 | 3 | 2 | 1 | - | 6 | 3 | | | | | | | | | | | | |
| Titer Positive Infected Mice (n=4) | Cmu Ag | - | 41 | 163 | 6 | 31 | 45 | 286 | 71.5 | Amyloid | - | 44 | 63 | 10 | 17 | 44 | 175 | 44.5 | | | | | | | | | | | | |
| MoPn stock strain Day 60 p.i. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Titer Negative Infected mice (n=1) | Cmu Ag | - | - | 0 | 0 | 7 | - | 7 | 7 | Amyloid | - | - | 0 | 0 | 2 | - | 2 | 2 | | | | | | | | | | | | |
| Titer Positive Infected Mice (n=7) | Cmu Ag | 84 | 83 | 70 | 61 | 286 | 85 | 669 | 95.5 | Amyloid | 20 | 10 | 24 | 3 | 34 | 43 | 134 | 19.1 | | | | | | | | | | | | |

| Section Location (mm) | Rostral | | | | | | | | | | Bregma | | | | | | | | | | Caudal | | | | | | | | | |
|--------------------------------------|---------|-------|-------|-------|-------|-------|-------|-------------|-------|-------|--------|-------|-------|-------|-------|-------------|--|--|--|--|--------|--|--|--|--|--|--|--|--|--|
| | -0.92 | -1.28 | -2.12 | -2.75 | -3.80 | -4.20 | Total | Total/Mouse | -0.92 | -1.28 | -2.12 | -2.75 | -3.80 | -4.20 | Total | Total/Mouse | | | | | | | | | | | | | | |
| MoPn in vivo Day 60 p.i. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Titer Negative Infected mice (n=2) | GFAP | 2.31 | 1.93 | 0.76 | - | 2.20 | 1.66 | 836 | 418 | | | | | | | | | | | | | | | | | | | | | |
| Titer Positive Infected mice (n=4) | GFAP | 2.83 | 1.70 | 1.54 | 0.58 | 2.10 | 1.56 | 1627 | 407 | | | | | | | | | | | | | | | | | | | | | |
| MoPn stock strain Day 60 p.i. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Titer Negative Infected mice (n=1) | GFAP | 4.09 | 2.57 | - | 2.03 | 1.04 | 1.23 | 616 | 616 | | | | | | | | | | | | | | | | | | | | | |
| Titer Positive Infected mice (n=4) | GFAP | 1.29 | 3.82 | 7.89 | 0.95 | 1.13 | 4.54 | 3851 | 963 | | | | | | | | | | | | | | | | | | | | | |

Glial Fibrillary Acid Protein (GFAP) Labeling
GFAP-specific labeling of CNS tissue of BALB/c mice inoculated i.n. with 100,000 IFU MoPn Weiss (MoPn stock strain) (A and C) or CSW (MoPn *in vivo* passaged) (B and D) immunolabeled with GFAP-specific antibody. E and F represent tier positive control tissue which were immunolabeled with GFAP-specific. Bar=50 microns.

Chlamydia (Cmu) Antigen, Amyloid Deposition, and GFAP immunoreactivity
Location of *C. muridarum* immunoreactivity and amyloid deposition at day 60 post infection within the brains of mouse pneumonitis *in vivo* passage and mouse pneumonitis stock strain infected mice. The location of the immunoreactive label to amyloid, chlamydial antigen, or GFAP is designated in millimeters (section location in mm) rostral or caudal to the mouse bregma. The dash mark (-) indicates that no data was collected.



Conclusions

- Amyloid deposition at the 2 month time point in mice intranasally infected with *Chlamydia muridarum* demonstrates that infection with this bacterium induces amyloid pathology.
- Chlamydia and amyloid antigen totals at day 60 p.i. in the titer positive mice of both the MoPn *in vivo* and MoPn stock strain demonstrated significant labeling relative to titer negative mice in both groups demonstrating that those mice who had an established infection were at greater risk for developing AD-like pathology.
- Glial cell activation observed in MoPn *in vivo* titer positive group was not elevated relative to titer negative controls, but a 50% elevation was noted in the brains of MoPn stock strain titer positive mice relative to the titer negative control.
- Amyloid and chlamydia antigen totals per mouse at day 60 p.i. with *Chlamydia muridarum* vs. Cpn-AR39 suggest that both strains of chlamydia initiate early AD-like pathology.

Acknowledgments

I would like to thank Maria Johnson and Benjamin Szuhaif for their help labeling and analyzing tissue. Thank you to Chris Hammond for technical assistance and help throughout my research. A special thanks to Gwendolyn Harley for sectioning tissue.

Bibliography

- 2011 Alzheimer's disease facts and figures. *Alzheimer's Association*. 2011;7(2):1-63.
- Blennox K, de Leon MJ, Zetterberg H. Alzheimer's disease. *Lancet*. 2006;368(9533):387-403.
- Nolte J. *The human brain: An introduction to its functional anatomy*. 6th ed. Philadelphia: Mosby Elsevier; 2009:720.
- St George-Hyslop PH, Petit A. Molecular biology and genetics of Alzheimer's disease. *Comptes Rendus Biologies*. 2005;328(2):119-130.
- Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. *Science*. 2002;297(5580):353-356.
- Wyss-Coray T. Inflammation in Alzheimer disease: Driving force, bystander or beneficial response? *Nat Med*. 2006;12(9):1005-1015.
- Balin BJ, Gerard HC, Arking EJ, et al. Identification and localization of chlamydia pneumoniae in the Alzheimer's brain. *Medical Microbiology and Immunology*. 1998;187(1):23-42.
- Peeling RW, Brunham RC. Chlamydiae as pathogens: New species and new issues. *Emerging Infectious Diseases*. 1996;2(4):307-319.
- Rizzo A, di Domenico M, Carratelli CR, Paolillo R. The role of chlamydia and chlamydia-like infections in reactive arthritis. *Internal Medicine*. 2012;51(1):113-117.
- Siala M, Gdoura R, Younes M, et al. Detection and frequency of chlamydia trachomatis DNA in synovial samples from tunisian patients with reactive arthritis and undifferentiated oligoarthritis. *FEMS Immunol Med Microbiol*. 2009;55(2):178-186.
- Jha R, Srivastava P, Salhan S, et al. Spontaneous secretion of interleukin-17 and -22 by human cervical cells in the chlamydia trachomatis infection. *Microb Infect*. 2011;13(2):167-178.
- Murthy AK, Sharma J, Coalsion JJ, Zhong G, Arulanandam BP. Chlamydia trachomatis pulmonary infection induces greater inflammatory pathology in immunoglobulin A deficient mice. *Cell Immunol*. 2004;230(1):56-64.
- Stephens RS. The cellular paradigm of chlamydial pathogenesis. *Trends Microbiol*. 2003;11(1):44-51.
- Straiton CW, Siram S. Association of chlamydia pneumoniae with central nervous system disease. *Microb Infect*. 2003;5(13):1249-1253.
- Hammerschlag MR. The intracellular life of chlamydia. *Seminars in Pediatric Infectious Diseases*. 2002;13(4):239-248.
- Little CS, Hammond CJ, MacIntyre A, Balin BJ, Appelt DM. Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. *Neurobiol Aging*. 2004;25(4):419-429.
- Balin B, Appelt D. Role of infection in Alzheimer's disease. *JAOA: Journal of the American Osteopathic Association*. 2001;101(12 suppl 1):1S-6S.